165 related articles for article (PubMed ID: 24328406)
1. Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
Bhatt VR; Ganti AK
Future Oncol; 2014 Jan; 10(1):17-20. PubMed ID: 24328406
[No Abstract] [Full Text] [Related]
2. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
3. Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Lin CL; Chiang WF; Tung CL; Hsieh JL; Hsiao JR; Huang WT; Feng LY; Chang CH; Liu SY; Tsao CJ; Feng YH
Mol Med Rep; 2015 Jan; 11(1):547-54. PubMed ID: 25333206
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Lalami Y; Garcia C; Flamen P; Ameye L; Paesmans M; Awada A
Head Neck; 2016 Mar; 38(3):347-54. PubMed ID: 25332069
[TBL] [Abstract][Full Text] [Related]
5. Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Tamiya H; Kamo R; Kumei A; Yanagihara S; Ishii M; Kobayashi H
Clin Exp Dermatol; 2012 Oct; 37(7):749-52. PubMed ID: 22369131
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
7. Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
Möckelmann N; Rieckmann T; Busch CJ; Becker B; Gleißner L; Hoffer K; Omniczynski M; Steinmeister L; Laban S; Grénman R; Petersen C; Rothkamm K; Dikomey E; Knecht R; Kriegs M
Oncotarget; 2016 Apr; 7(17):23542-51. PubMed ID: 27015558
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
Laban S; Steinmeister L; Gleißner L; Grob TJ; Grénman R; Petersen C; Gal A; Knecht R; Dikomey E; Kriegs M
Radiother Oncol; 2013 Nov; 109(2):286-92. PubMed ID: 23953412
[TBL] [Abstract][Full Text] [Related]
9. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
11. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
[TBL] [Abstract][Full Text] [Related]
12. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
13. Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
Qiu YQ; Zhou J; Kang XS; Shen-Tu JZ; Ding LM; Tan FL; Guo J; Li LJ
Afr J Tradit Complement Altern Med; 2012; 9(3):431-9. PubMed ID: 23983378
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib for ovarian cancer.
Leone Roberti Maggiore U; Valenzano Menada M; Venturini PL; Ferrero S
Expert Opin Investig Drugs; 2013 Aug; 22(8):1049-62. PubMed ID: 23675696
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib for the treatment of multiple myeloma.
Gentile M; Martino M; Recchia AG; Vigna E; Morabito L; Morabito F
Expert Opin Investig Drugs; 2016 Jun; 25(6):743-9. PubMed ID: 26998658
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.
Mehta S; Moon J; Hashmi M; Leblanc M; Huang CH; Rinehart E; Wolf GT; Urba SG; Banerjee SK; Williamson S
Oncol Rep; 2013 Jun; 29(6):2095-100. PubMed ID: 23563900
[TBL] [Abstract][Full Text] [Related]
18. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
Affolter A; Samosny G; Heimes AS; Schneider J; Weichert W; Stenzinger A; Sommer K; Jensen A; Mayer A; Brenner W; Mann WJ; Brieger J
Head Neck; 2017 Apr; 39(4):623-632. PubMed ID: 28221700
[TBL] [Abstract][Full Text] [Related]
19. Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Mirantes C; Dosil MA; Eritja N; Felip I; Gatius S; Santacana M; Matias-Guiu X; Dolcet X
Eur J Cancer; 2016 Aug; 63():74-87. PubMed ID: 27288872
[TBL] [Abstract][Full Text] [Related]
20. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
[Next] [New Search]
